#Zosano Pharma

[columbianewsupdates]

Cluster Headache Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Segment | Companies – Eli Lilly and Company, Zosano Pharma, Mind Medicine (MindMed)

http://dlvr.it/SxJvmW

[parnasaha]

Wearable Injectors Market Market 2022 Rising Trend, Demand, Global Opportunity And Global Outlook

Wearable Injectors Market Market Description – Wearable Injectors Market size was valued at USD 6.66 billion in 2021 and is poised to grow from USD 7.65 billion in 2022 to USD 23.89 billion by 2030, growing at a CAGR of 15.29% in the forecast period (2023-2030).

Get Sample Copy of This Research Report Here: https://www.skyquestt.com/sample-request/wearable-injectors-market Wearable Injectors Market Market includes Market Analysis Report Top Companies:

Ypsomed

Amgen

Subcuject (Denmark)

Becton, Dickinson and Company (BD)

Bespak Europe Ltd.

CeQur SA

Debiotech SA

Enable Injections

Insulet Corporation

Medtronic plc

Mylan N.V.

Nemera Development S.A.

Omron Corporation

Pfizer Inc.

Roche Holding AG

Sensile Medical AG

SteadyMed Therapeutics, Inc.

Tandem Diabetes Care, Inc.

United Therapeutics Corporation

West Pharmaceutical Services, Inc.

Zosano Pharma Corporation

Regional Analysis for Wearable Injectors Market Market:

The key manufacturers in the market are mentioned in this section of the report. It helps the reader in grasping the tactics and alliances that participants are adopting to resist market competition. The extensive research offers an important microscopic view of the market. Analyzing the regional revenue of manufacturers during the predicted period will enable the reader to locate their geographic footprints.

Read This Wearable Injectors Market Market Full Report Here: https://www.skyquestt.com/report/wearable-injectors-market

The base on geography, the world market of Wearable Injectors Market Market has been segmented as follows:

 North America includes the United States, Canada, and Mexico

 Europe includes Germany, France, the UK, Italy, Spain

 South America includes Colombia, Argentina, Nigeria, and Chile

 The Asia Pacific includes Japan, China, Korea, India, Saudi Arabia, and Southeast Asia

Important Features that are under Offering and Wearable Injectors Market Market Highlights of the Reports:

 A brief description of the Wearable Injectors Market Market

 Modifications to industry market dynamics

 A complete segmentation of the market by type, application, etc.

 Market size in terms of volume and value in the past, present, and future

 Current market trends and expansion

 The competitive environment in Wearable Injectors Market Market

 Prominent companies and product policies

 A potential niche market or territory that is growing quickly.

#Customization Service of the Report:

Wearable Injectors Market Market offers customized reports based on your requirements. To meet your specific needs, this report can be customized. Contact our sales team, who will ensure that you receive a report that meets your specifications.

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

[healthcaremarketfmi]

Pioneering Precision: Exploring the Microneedle Drug Delivery Systems Market Forecast 2023 to 2033

Emerging applications of microneedle drug delivery systems are expected to fuel their demand over the next decade. According to a recent report published by Future Market Insights (FMI), the global microneedle drug delivery systems market will grow at a CAGR of 6.6% between 2020 and 2030. The market is witnessing surging demand in the field of pharmacy and cosmetics.

The rising incidence of diseases such as cancer, diabetes, migraine, and others and the need to accurately administer medications are driving the market. Additionally, the demand for minimally invasive and painless treatment methods is expected to bode well for the market.

The report uncovers hidden growth opportunities. It also highlights potential threats to the market players. Some of the key takeaways from the report are highlighted below.

Key Takeaways from the Report

Solid microneedles are expected to lead the market during forecast period of 2020–2030 among product type

Hospitals are the leading end users of microneedle drug delivery systems, with specialty clinics gaining popularity.

Specialty clinics are expected to grow at an accelerated rate as one of the key end users of microneedle drug delivery systems

North America is the largest market for microneedle drug delivery systems. Along with Europe, it is expected to cover more than 70% of the market by end of 2030.

East Asia is expected to be the fastest-growing regional market during the next decade.

“Companies operating in the market are leaving no stone unturned to introduce innovations. Some have even tied up with leading solutions provider to commercialize their innovations once approved. This is expected to pave way for the market’s growth in the near future” said a lead Analyst at FMI.

Covid 19 Restricting Pace of Growth

The onset of pandemic has disturbed the entire business ecosystem. With productions coming to a halt and supply chains disrupted due to lack of transport, manufacturers of microneedle drug delivery systems are impacted in a big way.

Also, because of several restrictions by governments like social distancing, doctors and practitioners are choosing to avoid any surgical treatments which are not absolutely and immediately necessary.

Furthermore, cosmetic field which is another major user of microneedle drug delivery systems is also impacted as almost all treatments under their umbrella are considered to be not urgent.

The key market players in microneedle drug delivery systems market include the

3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko Corporation, Microdermics, Inc., TheraJect Inc., Vaxxas Pty Ltd., Endoderma Ltd., QuadMedicine, SNvia Co., Ltd., Small Lab and AdminMed Nano BioSciences LLC

Consolidating their positions through mergers, acquisitions and new product launches, global microneedle drug delivery systems market players rely heavily on new product innovation and differentiation for gaining an edge over their competitors.

The market is poised to grow during the forecast period owing to the increasing cases of diseases and needle phobia among patients. However, changing regulatory dynamics are expected to affect the growth of microneedle drug delivery systems market in the future.

For instance, Zosano Pharma’s clinical trial of zolmitriptan with microneedle drug delivery system was stopped by U. S. Food and Drug Administration because inconsistencies were found in the drug delivery.

For More Information: https://www.futuremarketinsights.com/reports/microneedle-drug-delivery-systems-market

[impossibledeanmakerwombat]

Microneedle Drug Delivery Systems Market to Latest Research, Industry Analysis, Driver, Trends, Business Overview, Key Value, Demand And Forecast 2022 to 2030

Emerging applications of microneedle drug delivery systems are expected to fuel their demand over the next decade. According to a recent report published by Future Market Insights (FMI), the global microneedle drug delivery systems market will grow at a CAGR of 6.6% between 2020 and 2030. Sales in the global microneedle drug delivery systems market are slated to increase at a healthy 6.6% CAGR over the forecast period, topping US$ 1.2 Bn by 2030, up from US$ 722.2 Mn in 2022. The market is witnessing surging demand in the field of pharmacy and cosmetics.

The rising incidence of diseases such as cancer, diabetes, migraine, and others and the need to accurately administer medications are driving the market. Additionally, the demand for minimally invasive and painless treatment methods is expected to bode well for the market.

The report uncovers hidden growth opportunities. It also highlights potential threats to the market players. Some of the key takeaways from the report are highlighted below.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2750

Key Takeaways from the Report

Solid microneedles are expected to lead the market during forecast period of 2020-2030 among product type

Hospitals are the leading end users of microneedle drug delivery systems, with specialty clinics gaining popularity.

Specialty clinics are expected to grow at an accelerated rate as one of the key end users of microneedle drug delivery systems

North America is the largest market for microneedle drug delivery systems. Along with Europe, it is expected to cover more than 70% of the market by end of 2030.

East Asia is expected to be the fastest growing regional market during the next decade.

Covid 19 Restricting Pace of Growth

The onset of pandemic has disturbed the entire business ecosystem. With productions coming to a halt and supply chains disrupted due to lack of transport, manufacturers of microneedle drug delivery systems are impacted in a big way.

Also, because of several restrictions by governments like social distancing, doctors and practitioners are choosing to avoid any surgical treatments which are not absolutely and immediately necessary.

Furthermore, cosmetic field which is another major user of microneedle drug delivery systems is also impacted as almost all treatments under their umbrella are considered to be not urgent.

Who is winning?

The key market players in microneedle drug delivery systems market include the 3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko Corporation, Microdermics, Inc., TheraJect Inc., Vaxxas Pty Ltd., Endoderma Ltd., QuadMedicine, SNvia Co., Ltd., Small Lab and AdminMed Nano BioSciences LLC

Full Report @ https://www.futuremarketinsights.com/reports/microneedle-drug-delivery-systems-market

[researchupdates]

Global Microneedle Drug Delivery Systems Market Growth Statistics to Make Multi-Billion Dollar Market during 2021-2028

Global Microneedle Drug Delivery Systems Market Synopsis:

DBMR team offers customization of Microneedle Drug Delivery Systems Market report according to the business needs. Contact sales team, who will guarantee to get a report that suits the necessities. The Market analysis and competitor analysis helps the firm in determining the range in terms of sizes, colors, designs, and prices, etc. within which its products are to be offered to the consumers. Microneedle Drug Delivery Systems Market survey report offers strategic and tactical support to clients for making well-informed business decisions. It is an organized method to bring together and document information about the Healthcare industry, Market, or potential customers.

The info covered in the universal Microneedle Drug Delivery Systems Market document helps businesses know how patents, licensing agreements and other legal restrictions affect the manufacture and sale of the firm’s products. It is helpful in determining the discount rates, the actual prices and the price ranges, price elasticity for its products. Such report is made available for industries, individuals, and organizations across the globe, and offerings are delivered in the shortest possible turnaround time. The report carefully examines the global Microneedle Drug Delivery Systems Market, with a focus on most of the major players and their business strategies, geographical scope, Market segments, product landscape and price, and cost structure.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-microneedle-drug-delivery-systems-market .

The Global Microneedle Drug Delivery Systems Market is growing at a CAGR of 7.10% in the forecast period of 2020 to 2027.

According to the market report analysis, Microneedles are tiny needles, small enough to be weighted millionths of a meter, designed to supply medicines which has many advantages for biological agents compared with conventional needle and syringe delivery systems. Microneedle delivery of drugs plays a significant role in the pharmaceutical, biotechnology and medical industries and is used in applications such as neurology, dermatology, cardiovascular, oncology and others.

Some of most important key factors driving the growth of the Global Microneedle Drug Delivery Systems Market are increasing demand for safer substitute to conventional hypodermic injections, increasing technologies such as microneedle patches, rising interest in alternate routes of drug administration transdermal and intradermal drug delivery systems, early phase disease diagnosis and treatment, rapidly growing population.

The major players covered in the Microneedle Drug Delivery Systems Market report are 3M, nanoBioSciences, LLC, NanoPass, Microdermics, Zosano Pharma Corp, Micropoint Technologies, MyLife Technologies, Innoture Medical Technology Limited, Phillips-Medisize - a Molex Company, Corium Inc, Stemedica Cell Technologies, Inc, and LTS Lohmann Therapie-Systeme AG among other domestic and global players.

Regionally, North America dominates the microneedle drug delivery systems market because of growing awareness among patients and rapidly growing population while APAC is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to changing lifestyle of people and rising per capita expenditure.

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-microneedle-drug-delivery-systems-market .

[stockcalc]

Calithera Biosciences (CALA:NAS) and Zosano Pharma (ZSAN:NAS) Are Biggest Stock Gainers YTD on NASDAQ

Calithera Biosciences (CALA:NAS) and Zosano Pharma (ZSAN:NAS) Are Biggest Stock Gainers YTD on NASDAQ

I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx. Biggest Stock Gainers Year to Date on NASDAQ Today we are looking at companies that have had the greatest percentage increase in share price year to date. Top 25 Companies Lists like these are always…

[reportwire]

Zosano Pharma cuts staff 31%, the latest layoffs in a wave of biotech belt-tightening - MedCity News

Zosano Pharma cuts staff 31%, the latest layoffs in a wave of biotech belt-tightening – MedCity News

  Zosano Pharma has been unable to sufficiently answer outstanding questions that led the FDA to turn down the regulatory submission for its migraine treatment, so now, running low on cash, the drug delivery biotech is turning to cost-saving measures that have already shaved headcount by nearly one third. Fremont, California-based Zosano disclosed the corporate restructuring in its report of…

[healthcaremarketfmi]

Microneedle Drug Delivery Systems Market Drivers and Restraints, Growth Opportunity Assessment and Forecast to 2033

 Emerging applications of microneedle drug delivery systems are expected to fuel their demand over the next decade. According to a recent report published by Future Market Insights (FMI), the global microneedle drug delivery systems market will grow at a CAGR of 6.6% between 2020 and 2030. The market is witnessing surging demand in the field of pharmacy and cosmetics.

The rising incidence of diseases such as cancer, diabetes, migraine, and others and the need to accurately administer medications are driving the market. Additionally, the demand for minimally invasive and painless treatment methods is expected to bode well for the market.

The report uncovers hidden growth opportunities. It also highlights potential threats to the market players. Some of the key takeaways from the report are highlighted below.

Key Takeaways from the Report

Solid microneedles are expected to lead the market during forecast period of 2020-2030 among product type

Hospitals are the leading end users of microneedle drug delivery systems, with specialty clinics gaining popularity.

Specialty clinics are expected to grow at an accelerated rate as one of the key end users of microneedle drug delivery systems

North America is the largest market for microneedle drug delivery systems. Along with Europe, it is expected to cover more than 70% of the market by end of 2030.

East Asia is expected to be the fastest-growing regional market during the next decade.

“Companies operating in the market are leaving no stone unturned to introduce innovations. Some have even tied up with leading solutions provider to commercialize their innovations once approved. This is expected to pave way for the market’s growth in the near future” said a lead Analyst at FMI.

Covid 19 Restricting Pace of Growth

The onset of pandemic has disturbed the entire business ecosystem. With productions coming to a halt and supply chains disrupted due to lack of transport, manufacturers of microneedle drug delivery systems are impacted in a big way.

Also, because of several restrictions by governments like social distancing, doctors and practitioners are choosing to avoid any surgical treatments which are not absolutely and immediately necessary.

Furthermore, cosmetic field which is another major user of microneedle drug delivery systems is also impacted as almost all treatments under their umbrella are considered to be not urgent.

For More Information: https://www.futuremarketinsights.com/reports/microneedle-drug-delivery-systems-market

The key market players in microneedle drug delivery systems market include the

3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko Corporation, Microdermics, Inc., TheraJect Inc., Vaxxas Pty Ltd., Endoderma Ltd., QuadMedicine, SNvia Co., Ltd., Small Lab and AdminMed Nano BioSciences LLC

Consolidating their positions through mergers, acquisitions and new product launches, global microneedle drug delivery systems market players rely heavily on new product innovation and differentiation for gaining an edge over their competitors.

The market is poised to grow during the forecast period owing to the increasing cases of diseases and needle phobia among patients. However, changing regulatory dynamics are expected to affect the growth of microneedle drug delivery systems market in the future.

For instance, Zosano Pharma’s clinical trial of zolmitriptan with microneedle drug delivery system was stopped by U. S. Food and Drug Administration because inconsistencies were found in the drug delivery.

[vivekbajaj-grs]

Microneedle Drug Delivery Systems Market - Global Outlook and Forecast 2021-2027

This report contains market size and forecasts of Microneedle Drug Delivery Systems in Global, including the following market information:

Global Microneedle Drug Delivery Systems Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-microneedle-drug-delivery-systems-market-2021-2027-985

The global Microneedle Drug Delivery Systems market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

We surveyed the Microneedle Drug Delivery Systems companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Microneedle Drug Delivery Systems Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Microneedle Drug Delivery Systems Market Segment Percentages, By Type, 2020 (%)

Hollow Microneedle Technology

Solid Microneedle Technology

Dissolving Microneedles Technology

China Microneedle Drug Delivery Systems Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Microneedle Drug Delivery Systems Market Segment Percentages, By Application, 2020 (%)

Drug Delivery

Vaccine Delivery

Global Microneedle Drug Delivery Systems Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Microneedle Drug Delivery Systems Market Segment Percentages, By Region and Country, 2020 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Microneedle Drug Delivery Systems Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Microneedle Drug Delivery Systems Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

KINDEVA

Zosano Pharma

Becton-Dickinson(BD)Technologies

Nanopass Technologies

Corium

Valeritas

Nitto

Microdermics

TheraJect, Inc

Vaxxas

Lohmann Therapie-Systeme AG

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-microneedle-drug-delivery-systems-market-2021-2027-985

Table of content

1 Introduction to Research & Analysis Reports 1.1 Microneedle Drug Delivery Systems Market Definition 1.2 Market Segments 1.2.1 Market by Type 1.2.2 Market by Application 1.3 Global Microneedle Drug Delivery Systems Market Overview 1.4 Features & Benefits of This Report 1.5 Methodology & Sources of Information 1.5.1 Research Methodology 1.5.2 Research Process 1.5.3 Base Year 1.5.4 Report Assumptions & Caveats 2 Global Microneedle Drug Delivery Systems Overall Market Size 2.1 Global Microneedle Drug Delivery Systems Market Size: 2021 VS 2027 2.2 Global Microneedle Drug Delivery Systems Market Size, Prospects & Forecasts: 2016-2027 2.3 Key Market Trends, Opportunity, Drivers and Restraints 2.3.1 Market Opportunities & Trends 2.3.2 Market Drivers 2.3.3 Market Restraints 3 Company Landscape 3.1 Top Microneedle Drug Delivery Systems Players in Global Market 3.2 Top Global Microneedle Drug Delivery Systems Companies Ranked by Revenue 3.3 Global Microneedle Drug Delivery Systems Revenue by Companies 3.4 Top 3 and Top 5 Microneedle Drug Delivery Systems Companies in Global Market, by Revenue in 2020 3.5 Global Companies Microneedle Drug Delivery Systems Product Type 3.6 Tier 1, Tier 2 and Tier 3 Microneedle Drug Delivery Systems Players in Global Market 3.6.1 List of Global Tier 1 Microneedle Drug Delivery Systems Companies

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/

[blogaarti]

Microneedle Drug Delivery Market Report 2021, By Segmentations, Key Company Profiles and Demand Forecasts to 2025

Billions of injections are administered worldwide on an annual basis. Nonetheless, the conventional approach via hypodermic needles is problematic due to risks involved with needle injuries, pain perception, and skin transport barrier limits. Intended as a minimally invasive and painless system, microneedle arrays (MNA) are an ideal solution for the transdermal delivery of drugs. Its ability to bypass the stratum corneum makes it a superior alternative to subcutaneous injections or other types of transdermal delivery systems such as chemical enhancers or microparticles. The primary objective of microneedles is to penetrate the skin with microscopic holes and disrupt the stratum corneum. 

Get a Sample Copy of Microneedle Drug Delivery Market: https://www.fairfieldmarketresearch.com/report/microneedle-drug-delivery-market/request-sample

Microneedles Minimize Patient Trypanophobia Aiding Immunisation Programmes

Microneedle drug delivery offers several advantages including faster onset, improved efficacy, and higher patient compliance. Microneedles provide therapeutic advantages and deliver reproducible results with pinpoint accuracy and minimal variability in bioavailability. As a painless mechanism for drug delivery, microneedles aid in overcoming trypanophobia that is the fear of needles increasing adoption rates in the paediatrics segment and boosting mass immunisation programmes. Drug delivery can be controlled with higher efficiency than other transdermal drug delivery methods.   

Microneedle Companies Sharing IP With Vaccine Manufacturers to Guarantee Success

NanoPass Technologies, a key player in the microneedle drug delivery market, has decided to collaborate with immunotherapy companies to use its proprietary MicronJet assisting their efforts in creating an affordable, effective, and safe COVID-19 vaccine. Other companies involved in the microneedle drug deliver market are 3M, Microdermics, Zosano Pharma Corporation (ZSAN), Nitto Denko Corporation, Becton, Dickinson and Company, Vaxxas Pty Ltd, Valeritas (Zealand Pharma A/S), Corium, Inc., TheraJect, Inc., LTS Lohmann Therapie-Systeme AG, and Alza Corporation. 

Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.fairfieldmarketresearch.com/report/microneedle-drug-delivery-market/request-customization

Versatility of Microneedle Arrays Makes Them Perfect For Oral and Buccal Drug Delivery

There has been significant demand for therapies where active substances are not properly absorbed through oral administration. In addition, newer nanoparticle and microparticle drug encapsulation technologies have been invented with the number of registered patents growing by leaps and bounds. Transdermal administration shows immense promise with ovalbumin the most common protein antigen for immunisation studies with microneedle arrays. In the 21st century, cosmetics undergo maximum clinical trials with microneedle arrays and there has been rising interest for microneedles in diagnostics. Microneedle arrays can massively impact the wearable epidermal diagnostic device segment as a result of their unique attributes. Microneedle array transdermal drug delivery and patient preference for minimally invasive procedures opens up limitless opportunities for rectal, oral, ocular, and buccal drug delivery. 

Low Manufacturing Cost Enables Hollow Microneedle Array Segment to Remain Popular

There are four types of fabrication available in the microneedle drug delivery market – dissolving, hollow, hydrogel, and solid microneedle arrays. Solid microneedles are manufactured from silicon or metal, are time-tested, and have a longer product lifespan. However, there has been a notable uptick in polymer microneedle arrays in the last five years. Hollow microneedle arrays usually deliver a better API quality than all other options in the microneedle drug delivery market. Furthermore, precise drug control, low cost and ease of manufacturing all work in favour of hollow microneedle arrays making them a popular choice in the microneedle drug delivery market. 

Browse Our Latest Trending Reports:  https://www.fairfieldmarketresearch.com/industry/all

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

[kritikarehani]

Cluster Headaches Market Size, Share, Trends, Epidemiology and Market Forecast 2030

Cluster Headache (CH) Overview

Cluster Headache is a major headache and is very common in a group of head problems called trigeminal autonomic cephalalgias. The term cluster headache comes from the fact that the attack occurred in groups, or “clusters.” During the group cycle, severe headaches also occur between 1─8 times a day. Cluster cycles can last for weeks or months and are usually terminated during periods of remission, or periods of headaches. It usually occurs at the age of 20-40 and this condition is more common in men than women. It contains a headache on one side of the head. It is related to symptoms that occur on the same side of the head where the pain persists, runny or crooked nose, including red or clear eye, and spraying or sweating of the face.

Cluster Headache Causes

●     The exact cause of cluster heads is unknown, but cluster patterns suggest that abnormalities in the body's hypothalamus play a role.

●     Unlike migraine and tension headache, cluster headache is usually not associated with causes, such as diet, hormonal changes, or depression.

●     As soon as the collection time begins, however, alcohol consumption can quickly start a divisive headache. For this reason, many people with a cluster head avoid alcohol during the collection.

●     Other possible causes include the use of drugs such as nitroglycerin, a drug used to treat heart disease.

Cluster Headache Signs and Symptoms

The cluster's head strikes quickly, usually without warning, although you may begin to experience nausea such as migraine and aura. Common signs and symptoms during a headache include:

1.    Pain on one side

2.    Instability

3.    Extreme sadness

4.    Redness of your eye on the affected side

5.    The stuffy or runny nose on the affected side

6.    Forehead or facial sweating on the affected side

7.    Pale skin or wrinkles on your face

8.    Swelling around your eye on the affected side

9.    Drooping eyelid to the affected side

Unlike those with migraines, people with cluster headaches are more likely to walk faster or stay back and forth. Other symptoms such as migraine - including sensitivity to light and noise - can occur with the head of the group, however on one side.

Cluster Headache (CH) Epidemiology Insights

According to the World Health Organization (WHO) cluster headache is comparatively rare and it affects fewer than one in 1,000 adults which affects six men to each woman (“Headache disorders,” n.d.)

According to the research study of Fischera et al., the pooled data for cluster headache showed that the lifetime prevalence of 124 per 100,000 and a 1 year prevalence of 53 per 100,000 (Fischera, Marziniak, Gralow, & Evers, 2008).

Cluster Headache (CH) Market Outlook

Cluster headache is a neurovascular rather than a vascular headache, with vascular cerebral changes being focused by the effects of trigeminal-autonomic reflex activation. The trigeminal-autonomic reflex is a pathway that consists of a brainstem linking between the trigeminal nerve and facial cranial nerve parasympathetic outflow and is activated with the stimulation of the trigeminovascular pathways.

There is an advancement in the understanding of the cluster headache pathophysiology, which has led to the improved characterization and diagnosis of the clinical features. For treatment to be effective, the correct diagnosis must be made followed by choice of treatment, taking into account the severity and frequency of attacks, other symptoms, patient preference, history of treatment, and comorbid conditions.

The dynamics of the Cluster Headache market is expected to change in the coming years owing to the improvement in the diagnosis methodologies, increasing awareness of the disease, and incremental healthcare spending across the world. Key players in the therapeutic market of Cluster Headache are Zosano Pharma and Mind Medicine (MindMed) etc. The launch of emerging therapies, such as LSD (Mind Medicine (MindMed)) and C213 Microneedle System (Zosano Pharma) will significantly impact the Cluster Headache market during the forecast period (2020–2030).

[markettrendus]

Microneedle Drug Delivery Systems Market qualitative and quantitative analysis by segments, regions, top players and forecast, 2021-2029 | 3M, Microdermics, Zosano Pharma, Nitto

Microneedle Drug Delivery Systems Market qualitative and quantitative analysis by segments, regions, top players and forecast, 2021-2029 | 3M, Microdermics, Zosano Pharma, Nitto

Global Microneedle Drug Delivery Systems Market Overview: Global Microneedle Drug Delivery Systems Market Report 2021 comes with the extensive industry analysis of development components, patterns, flows, and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2029. This research study of Microneedle…

[massimo-daniele-iafisco]

Zosano Pharma Buy

from Latest Analyst Opinions - markets.businessinsider.com https://ift.tt/2Nl3IHb via https://ift.tt/2PMofEJ

[tpentzek]

Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo?

[ericvick]

Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data

Here’s a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs Jan. 4)

ABIOMED, Inc. (NASDAQ: ABMD)

Arvinas Inc (NASDAQ: ARVN)

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

Bioanalytical Systems, Inc. (NASDAQ: BASI)

BioNano Genomics Inc (NASDAQ: BNGO) (said its subsidiary Lineagen’s genetic tests identified novel variants in known autism risk genes)

BridgeBio Pharma Inc (NASDAQ: BBIO)

Clearpoint Neuro Inc (NASDAQ: CLPT)

Curis, Inc. (NASDAQ: CRIS)

DiaMedica Therapeutics Inc (NASDAQ: DMAC)

Eidos Therapeutics Inc (NASDAQ: EIDX) (proxy advisory firm Institutional Shareholder Services recommended Eidos merger with BridgeBio)

Endo International PLC (NASDAQ: ENDP)

Fulgent Genetics Inc (NASDAQ: FLGT)

I-Mab ADR (NASDAQ: IMAB)

Jaguar Health Inc (NASDAQ: JAGX)

Masimo Corporation (NASDAQ: MASI)

Ocugen Inc (NASDAQ: OCGN) (reacted to its Indian partner receiving conditional approval for coronavirus vaccine in the Indian market)

Organogenesis Holdings Inc (NASDAQ: ORGO)

Otonomy Inc (NASDAQ: OTIC)

PMV Pharmaceuticals Inc (NASDAQ: PMVP)

PRA Health Sciences Inc (NASDAQ: PRAH)

Precigen Inc (NASDAQ: PGEN)

Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN)

TRACON Pharmaceuticals Inc (NASDAQ: TCON)

United Therapeutics Corporation (NASDAQ: UTHR)

Vincera Pharma Inc (NASDAQ: VINC)

Vistagen Therapeutics Inc (NASDAQ: VTGN)

X T L Biopharmaceuticals Ltd (ASDAQ: XTLB)

Down In The Dumps

(Biotech Stocks Hitting 52-week Lows Jan. 4)

4D Molecular Therapeutics Inc (NASDAQ: FDMT)

Aprea Therapeutics Inc (NASDAQ: APRE)

Calithera Biosciences Inc (NASDAQ: CALA) (reported adverse outcome for the Phase 2 study of telaglenastat in patients with advanced or metastatic renal cell carcinoma)

Intercept Pharmaceuticals Inc (NASDAQ: ICPT)

Vivos Therapeutics Inc (NASDAQ: VVOS)

Stocks In Focus Moderna Gets Israeli Regulatory Nod For Coronavirus Vaccine Candidate

Moderna Inc (NASDAQ: MRNA) announced that Israel’s Ministry of Health has given authorization to import Moderna’s mRNA-1273, its vaccine candidate against the novel coronavirus. 

Story continues

“This is the third regulatory authorization for the COVID-19 Vaccine Moderna, and its first outside of North America,” said Stéphane Bancel, CEO of Moderna.

“We hope to continue to see authorizations in additional markets in the coming days, weeks and months.”

Israel has secured 6 million doses of mRNA-1273 and first deliveries are expected to begin shortly, the company said.

The stock was up 1.14% to $113 in premarket trading. 

Roche’s Cancer Drug Combo Gets Breakthrough Therapy Designation For Lung Cancer

Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA granted breakthrough therapy designation for tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, in combination with Tecentriq for the first-line treatment of people with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations

The stock edged up 0.22% to $44 in after-hours trading.

Gritstone Oncology Rallies On Insider, Fund Buying

Gritstone Oncology Inc (NASDAQ: GRTS) shares rallied in reaction to a filing which revealed that biotech-focused hedge fund EcoR1 Capital, LLC built up a 9.9% stake in the company.

A separate filing showed Thomas Woiwode, a member of the company’s board of directors, bought 1.35 million shares in the company at $3.71 each. 

The stock was jumping 19.16% higher to $4.85 premarket Tuesday. 

Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

Tonix to Collaborate With Massachusetts General Hospital For Organ Transplant Rejection Treatment

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced the signing of a second research collaboration agreement with Massachusetts General Hospital to develop TNX-1500, a humanized monoclonal antibody that targets the CD40-ligand for the prevention and treatment of organ transplant rejection.

In premarket trading Tuesday, Tonix shares were jumping 8.39% to 78 cents.

Marker Announces Lifting of Clinical Hold On Acute Myeloid Leukemia Study

Marker Therapeutics, Inc. (NASDAQ: MRKR) said the FDA lifted the partial clinical hold on its Phase 2 trial investigating the safety and efficacy of MT-401, its lead, multi-tumor-associated, antigen-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia.

BioXcel Says BXCL501 Aces Phase 1b/2 Study In Treating Dementia-Related Agitation

BioXcel Therapeutics Inc (NASDAQ: BTAI) said its BXCL501, an orally dissolving thin film formulation of dexmedetomidine, met the primary and secondary endpoints of the TRANQUILITY Phase 1b/2 trial that evaluated the pipeline asset at the 60 mcg dose level for treating agitation related to dementia, including Alzheimer’s disease.

Topline results from the evaluated doses showed that BXCL501 was generally well-tolerated, with rapid and durable reductions observed in measures of acute agitation with the 60 mcg dose. 

The stock was moving up 7.77% to $56.31 in premarket trading Tuesday.

Myovant’s Recently Approved Prostate Cancer Treatment Now Available In US

Myovant Sciences Ltd (NYSE: MYOV) announced the U.S. commercial availability of Orgovyx, the first and only oral gonadotropin-releasing hormone receptor antagonist approved by the FDA, for the treatment of adult patients with advanced prostate cancer.

In premarket trading Tuesday, Myovant shares were adding 3.06% to $25.59. 

Checkmate Names Pharma Industry Veteran Robert Dolski As CFO

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) announced the appointment of biopharma industry veteran Robert Dolski as its chief financial officer.

The company also said it recently strengthened its leadership team by naming Katherine Eade as General Counsel.

aTyr’s Lead Candidate Aces Midstage Study In Hospitalized COVID-19 Patients

aTyr Pharma Inc (NASDAQ: LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation.

The trial met its primary endpoint of safety, demonstrating that a single, intravenous dose of ATYR1923 was generally safe and well-tolerated in both the 1.0 and 3.0 mg/kg treatment groups, with no drug-related serious adverse events, the company said.

“We are very encouraged by the signal of clinical activity seen in the 3.0 mg/kg cohort of ATYR1923. The relatively faster time to recovery seen by adding a single dose of ATYR1923 to standard of care treatment and the greater proportion of patients recovering within a week compared to placebo give us further confidence in this signal,” said Sanjay Shukla, CEO of aTyr.

The stock was up 6.8% premarket at $4.24. 

Zosano Requests FDA Meeting On Migraine Drug Application

Zosano Pharma Corp (NASDAQ: ZSAN) said on Dec. 30 that the company requested a Type A meeting with the FDA.

The purpose of the Type A meeting is to receive FDA input on the requirements for the resubmission of the NDA for its migraine treatment candidate Qtrypta following the complete response letter received on Oct. 20.

The FDA typically responds to a sponsor’s request for a Type A meeting, if granted, with a meeting scheduled within 30 days from the receipt of the request.

Zosano shares were trading 42.93% higher at 83 cents premarket Tuesday. 

Cerecor Announces Positive Results Phase 2 Study Of CERC-002 In Hospitalized COVID-19 Patients

Cerecor Inc (NASDAQ: CERC) announced positive results from its exploratory, Phase 2 U.S.-based proof of concept trial of the human anti-LIGHT monoclonal antibody CERC-002 in hospitalized patients with COVID-19 associated pneumonia and mild-to-moderate acute respiratory distress syndrome.

The trial demonstrated robust improvement in the primary endpoint — the proportion of patients alive and free of respiratory failure over the 28-day study period — compared to placebo.

The stock was jumping 24.62% to $3.29 in premarket trading Tuesday.

ImmunoGen Insiders Buy Shares

ImmunoGen, Inc. (NASDAQ: IMGN) shares moved to the upside after a series of filings revealed purchase of the company’s shares by company insiders.

In after-hours trading, the stock gained 5.93% to $6.88.

Puma Biotechnology Shares Drop On Insider Selling

Puma Biotechnology Inc (NASDAQ: PBYI) shares came under pressure after a SEC filing on Form 4 revealed that its CEO Alan Auerbach sold 355 shares in the company at $11.656 per share. A separate filing showed that Richard Bryce, the company’s chief medical and scientific officer sold 92 shares at a price of $11.65 per share.

The stock shed 5.52% to $9.76 in after-hours trading.

Offerings

Generation Bio Co (NASDAQ: GBIO) said in a filing it plans to offer 7.5 million shares of its common stock in a follow-on offering.

In after-hours trading, the stock slipped 4.42% to $28.75.

Fate Therapeutics Inc (NASDAQ: FATE) said it has commenced an underwritten public offering of $350 million in shares of common stock.

The company said it intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, the conduct of preclinical R&D, and for general corporate purposes.

The stock was down 4.10% to $86 in after-hours trading.

Prelude Therapeutics Inc (NASDAQ: PRLD) said it has commenced a public offering of 1.75 million shares of its common stock in a follow-on offering. All shares of common stock to be sold in the offering will be sold by the company.

NGM Biopharmaceuticals Inc (NASDAQ: NGM) said it has commenced an underwritten public offering of $100 million in shares of its common stock. All of the shares in the proposed offering will be sold by the company.

In after-hours trading, the stock fell 2.63% to $28.48.

On The Radar Clinical Readouts

Mersana Therapeutics Inc (NASDAQ: MRSN) is scheduled to release updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b. The presentation is due at the company’s virtual analyst and investor event.

Related Link: SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.